According to a new report from the World Health Organization (WHO) released yesterday, antibiotics development at present is not at par with the rising antimicrobial resistance worldwide and soon the demand may outgrow the supply. The WHO warns that this could mean that pathogens causing these infections could mean a great threat for humans in the coming years.

What's worse than getting exposed to a kind of bacteria that modern antibiotics can't kill? Getting exposed to more than one - because they may work together to cause an infection, new research suggests.

A new study has found that the complex mixture of sugars, proteins and fats in mother’s milk possesses certain properties that can protect babies against bacterial infections like Streptococci too. Researchers from Vanderbilt University looked at the antibacterial properties of breast milk and found that the sugars in it have antibacterial properties and also work to enhance the antibacterial properties of the proteins in breast milk.

Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhea will enter pivotal trials, thanks to a new partnership between the not-for-profit Global Antibiotic Research and Development Partnership and Entasis Therapeutics.

Scientists and physicians at University of California San Diego School of Medicine, working with colleagues at the U.S. Navy Medical Research Center - Biological Defense Research Directorate, Texas A&M University, a San Diego-based biotech and elsewhere, have successfully used an experimental therapy involving bacteriophages -- viruses that target and consume specific strains of bacteria -- to treat a patient near death from a multidrug-resistant bacterium.

Scientists at St. Boniface Hospital Albrechtsen Research Centre and the University of Manitoba have developed a drug that combats 2 of the top 10 "priority pathogens" recently defined by the World Health Organization as antiobiotic-resistant bacteria requiring new interventions.

Since the discovery of penicillin in 1928, antibiotics have made the world a much safer and healthier place. But Shakespeare was onto something when he asked if it's possible to have too much of a good thing. In the case of antibiotics, the answer is increasingly "yes."

Airports are international travel hubs visited by large numbers of people. London Heathrow, for example, has an average of 205,400 travellers every day and saw 75 million people arriving and departing from all over the world in 2015.

Good news for the millions of people who suffer from skin wounds that won't heal. A team of researchers at The Ohio State University has brought a potentially transformative solution to the problem by creating a portable adhesive patch that drives a continuous, small electrical current to stimulate healing and reduce the risk of infection.

An exhaustive look at how bacteria hold their ground and avoid getting pushed around by their environment shows how dozens of genes aid the essential job of protecting cells from popping when tensions run high.

Tiny molecular scaffolding that joins molecules together could be the key to our battle against antibiotic resistance. Research published in Bioorganic & Medicinal Chemistry Letters shows that carbon nanodot scaffolding assembled with small molecules called polyamines can kill some dangerous drug-resistant bacteria, including Acinetobacter baumanii and Klebsiella pneumonia.

A research team led by University of Arkansas chemist Jingyi Chen and University of Arkansas for Medical Sciences microbiologist Mark Smeltzer has developed an alternative therapeutic approach to fighting antibiotic-resistant infections.

Researchers at the University of Michigan Life Sciences Institute and School of Public Health have discovered a new class of anti-biofilm compounds derived from marine microorganisms that show promise against a drug-resistant bacterium commonly associated with hospital-acquired infections.

Naturally occurring clay from British Columbia, Canada -- long used by the region's Heiltsuk First Nation for its healing potential -- exhibits potent antibacterial activity against multidrug-resistant pathogens, according to new research from the University of British Columbia.

Leveraging the mass production benefit that MultiBrain® technology brings to neurohistology, NSA can accelerate the R&D preclinical and safety assessment processes many fold and perform them less expensively. This results in faster times for a potential drug to move from R&D to clinical trials and sooner for use in people.

Pittcon is an analytical conference, so naturally my talk will be about analytical chemistry and how analytical chemistry will become increasingly important in delivering healthcare solutions, not only for rich people, but also, hopefully, for poor people across the world.

Other Useful Links

News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.